PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 9, 2025Frontiers in Oncology1 citationsOpen Access

Clinical value and molecular role of PRDXs family in prostate cancer

View Full Paper
YYYong YaoZQZheng QuanCQCheng Qian

Key Points

  • This research examines the role of peroxiredoxins in prostate cancer and their potential clinical applications.
  • Analyzed differentially expressed genes in Prostatic Adenocarcinoma using TCGA database.
  • Evaluated expression of peroxiredoxins in prostate cancer cells and tissues.
  • Conducted CCK8 and transwell assays to assess proliferation and invasion after silencing PRDX4.
  • Identified proteins interacting with PRDX4 and potential pathogenic sites.
  • PRDX2 and PRDX4 showed high expression in Prostatic Adenocarcinoma.
  • PRDXs family expression was higher in prostate cancer cells than in normal epithelial cells.
  • Silencing PRDX4 reduced proliferation and invasion capabilities of prostate cancer cells.
  • Identified 14 traditional Chinese medicines targeting PRDX4, with Shi Liu Zi showing potential effectiveness.

Abstract

Objectives The purpose of this study is to explore the clinical value and molecular role of the peroxiredoxins (PRDXs) family in prostate cancer (PCa). Methods We first analyzed the differentially expressed genes (DEGs) in Prostatic Adenocarcinoma (PRAD) using the Cancer Genome Atlas (TCGA) database, and then demonstrated the expression of six members of the PRDXs family in PRAD. Subsequently, we evaluated the expression of the PRDXs family using PCa cells and tissues. we also analyzed the diagnosis and overall survival (OS) of the PRDXs family in PCa. We used online tools to analyze the expression of PRDX4 in pan-cancer, the proteins interacting with it, as well as the amino acid regions and sites to pathogenicity. We used CCK8 and transwell assay to detect the proliferation and invasion of PCa cells after silencing PRDX4. Finally, we predicted traditional Chinese medicine drugs targeting PCa with PRDX4. Results We found that PRDX2 and PRDX4 were highly expressed in PRAD through the TCGA database. Compared with prostate epithelial cells, PRDX2, PRDX3, PRDX4, and PRDX6 were expressed higher in PCa cells. In PCa tissues, the PRDXs family is widely expressed positively (P0.05). The PRDXs family has relatively low diagnostic value in PCa, except for PRDX4. Based on the above results, we selected PRDX4 for molecular role detection. We found that the expression of PRDX4 in PCa was higher than that in more than half of the cancer types in pan-cancer. We found that there are eight proteins interacting with PRDX4. The pathogenic amino acid regions and sites of PRDX4 protein mutation that are prone to disease were mainly concentrated in the area after the 50th amino acid. We found that silencing PRDX4 slowed down the proliferation and invasion of PCa cells. Finally, we found that there are 14 traditional Chinese medicines targeting PCa with PRDX4, among which 5 have statistical differences, and Shi Liu Zi may be the best targeted traditional Chinese medicine drug. Conclusion This study found that PRDX4 is highly expressed in PCa, which may promote the phenotypic progression of PCa cells and has high clinical value.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yao et al. (2025) studied this question.

synapsesocial.com/papers/69401d5b2d562116f28f8b2bhttps://doi.org/10.3389/fonc.2025.1713670
Ask AI
Helpful
Bookmark
Share
View Full Paper